Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03754465 · ClinicalTrials.gov registry record · Phase 2
Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers
A Phase 2 study, sponsored by Anterogen Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT03754465 is a Phase 2 study that has completed, run by Anterogen Co.. The registered enrollment target is 66 participants.
The verdict
NCT03754465, a Phase 2 study, has completed, sponsored by Anterogen Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is a phase 2 double-blind clinical study to evaluate the efficacy and Safety of ALLO-ASC-SHEET in subjects with Diabetic Foot Ulcers, compared to placebo therapy.
Interventions
- BIOLOGICAL ALLO-ASC-DFU
- PROCEDURE Hydrogel SHEET(Vehicle control)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2019-01-02 |
| Est. Completion | 2023-10-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03754465
The ClinicalTrials.gov registry entry for NCT03754465 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anterogen Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ALLO-ASC-DFU is the first listed.
NCT03754465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03754465 about?
NCT03754465 is a clinical study titled "Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers". This is a phase 2 double-blind clinical study to evaluate the efficacy and Safety of ALLO-ASC-SHEET in subjects with Diabetic Foot Ulcers, compared to placebo therapy.
What is the current status of trial NCT03754465?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2019-01-02. Estimated completion is 2023-10-23.
What interventions are being tested in trial NCT03754465?
The interventions under investigation include: ALLO-ASC-DFU (BIOLOGICAL), Hydrogel SHEET(Vehicle control) (PROCEDURE).
Who is sponsoring clinical trial NCT03754465?
This trial is sponsored by Anterogen Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.